title: Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies.
abstract: OBJECTIVE
  The purpose of this study was to prospectively evaluate the efficacy and safety of micafungin (MCFG) in empirical therapy for febrile neutropenic patients for whom antibiotic therapy was not effective for hematological malignancies.
  
  
  METHODS
  Twenty-three hematological patients aged 27-82 years with febrile neutropenia for whom antibiotic therapy was not effective were enrolled in this study and responses to treatment were evaluated.
  
  
  RESULTS
  Treatment success rate was 73.9%. Treatment success rates by primary diagnosis were 77.8% in patients with AML, 50.0% in patients with NHL and 87.5% in patients with other diseases. Moreover, MCFG at a dose of 100 mg or more have a tendency to be effective. One or more adverse events occurred in five (27.7%) of the patients during the study. All of these adverse events were below grade 2 toxicity.
  
  
  CONCLUSIONS
  Although the number of patients studied was limited, MCFG as a monotherapy seems to be effective and safe as an empirical therapy in patients with febrile neutropenia. However, further investigation using large-scale studies is needed. This study demonstrated the clinical efficacy and safety of MCFG in patients with febrile neutropenia and with hematological malignancies.
authors.affiliation: Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo. ttoubai@hkg.odn.ne.jp
authors.forename: Tomomi
authors.initials: T
authors.lastname: Toubai
authors.forename: Junji
authors.initials: J
authors.lastname: Tanaka
authors.forename: Shuichi
authors.initials: S
authors.lastname: Ota
authors.forename: Akio
authors.initials: A
authors.lastname: Shigematsu
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Shono
authors.forename: Makoto
authors.initials: M
authors.lastname: Ibata
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hashino
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kondo
authors.forename: Yasutaka
authors.initials: Y
authors.lastname: Kakinoki
authors.forename: Nobuo
authors.initials: N
authors.lastname: Masauzi
authors.forename: Masaharu
authors.initials: M
authors.lastname: Kasai
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Iwasaki
authors.forename: Mitsutoshi
authors.initials: M
authors.lastname: Kurosawa
authors.forename: Masahiro
authors.initials: M
authors.lastname: Asaka
authors.forename: Masahiro
authors.initials: M
authors.lastname: Imamura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D054714:Echinocandins; D005260:Female; D005334:Fever / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D019337:Hematologic Neoplasms / Q000150:complications*; D006801:Humans; D055666:Lipopeptides; D008074:Lipoproteins / Q000009:adverse effects / Q000627:therapeutic use*; D008099:Liver / Q000503:physiopathology; D008297:Male; D000077551:Micafungin; D008875:Middle Aged; D009181:Mycoses / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D010456:Peptides, Cyclic / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D008074:Lipoproteins; D010456:Peptides, Cyclic; D000077551:Micafungin